[go: up one dir, main page]

MX373716B - Compuesto de pirazol-amida y sus usos farmaceuticos. - Google Patents

Compuesto de pirazol-amida y sus usos farmaceuticos.

Info

Publication number
MX373716B
MX373716B MX2015012743A MX2015012743A MX373716B MX 373716 B MX373716 B MX 373716B MX 2015012743 A MX2015012743 A MX 2015012743A MX 2015012743 A MX2015012743 A MX 2015012743A MX 373716 B MX373716 B MX 373716B
Authority
MX
Mexico
Prior art keywords
pyrazol
amide compound
pharmaceutical uses
formula
compound
Prior art date
Application number
MX2015012743A
Other languages
English (en)
Other versions
MX2015012743A (es
Inventor
Takahisa Motomura
Gakujun Shomi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51536938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX373716(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2015012743A publication Critical patent/MX2015012743A/es
Publication of MX373716B publication Critical patent/MX373716B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un compuesto representado por la siguiente fórmula (ver Fórmula) donde n es 1 o 2, (ver Fórmulas) o una de sus sales farmacéuticamente aceptables, y un uso farmacéutico de éstos.
MX2015012743A 2013-03-15 2014-03-14 Compuesto de pirazol-amida y sus usos farmaceuticos. MX373716B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361791164P 2013-03-15 2013-03-15
JP2013053195 2013-03-15
JP2013127318 2013-06-18
PCT/JP2014/056825 WO2014142290A1 (ja) 2013-03-15 2014-03-14 ピラゾール－アミド化合物およびその医薬用途

Publications (2)

Publication Number Publication Date
MX2015012743A MX2015012743A (es) 2016-02-19
MX373716B true MX373716B (es) 2020-05-08

Family

ID=51536938

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012743A MX373716B (es) 2013-03-15 2014-03-14 Compuesto de pirazol-amida y sus usos farmaceuticos.

Country Status (31)

Country Link
US (4) US9040717B2 (es)
EP (3) EP2975028B1 (es)
JP (6) JP6208603B2 (es)
KR (1) KR102226096B1 (es)
CN (1) CN105051015B (es)
AU (1) AU2014230569B2 (es)
BR (1) BR112015022077A2 (es)
CA (1) CA2904985C (es)
CL (1) CL2015002608A1 (es)
CY (1) CY1120173T1 (es)
DK (1) DK2975028T3 (es)
ES (1) ES2663789T3 (es)
HR (1) HRP20180635T1 (es)
HU (1) HUE036672T2 (es)
IL (1) IL241355B (es)
LT (1) LT2975028T (es)
ME (1) ME03090B (es)
MX (1) MX373716B (es)
MY (1) MY182884A (es)
NO (1) NO2975028T3 (es)
PE (1) PE20151595A1 (es)
PH (1) PH12015501993A1 (es)
PL (1) PL2975028T3 (es)
PT (1) PT2975028T (es)
RS (1) RS57188B1 (es)
RU (1) RU2664532C2 (es)
SG (1) SG11201507327TA (es)
SI (1) SI2975028T1 (es)
SM (1) SMT201800196T1 (es)
TW (1) TWI633885B (es)
WO (1) WO2014142290A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ES2790419T3 (es) 2013-01-15 2020-10-27 Incyte Holdings Corp Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM
PL2975028T3 (pl) * 2013-03-15 2018-10-31 Japan Tobacco, Inc. Związek pirazoloamidowy i jego zastosowania medyczne
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN109476609B (zh) * 2016-07-29 2022-06-14 日本烟草产业株式会社 吡唑-酰胺化合物的制造方法
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3747888A4 (en) * 2018-02-01 2021-12-15 Japan Tobacco Inc. NITROGEN-ENRICHED HETEROCYCLIC AMIDE COMPOUND AND USES THEREOF FOR MEDICAL PURPOSES
WO2020054734A1 (ja) 2018-09-11 2020-03-19 日本たばこ産業株式会社 ピラゾール－アミド化合物を含有する慢性腎臓病の治療又は予防剤
EP3936127B1 (en) 2019-03-04 2025-04-30 Japan Tobacco Inc. Amorphous solid dispersion of pyrazole-amide compound
PT4116301T (pt) * 2020-03-04 2025-11-12 Japan Tobacco Inc Composto tricíclico condensado e sua utilização medicinal
CN117897382A (zh) * 2021-09-01 2024-04-16 日本烟草产业株式会社 含氮三环化合物及其药物用途
KR102769218B1 (ko) * 2022-09-28 2025-02-24 주식회사 제이디바이오사이언스 신규한 플루오렌 유도체 및 이의 용도
WO2025079741A1 (ko) * 2023-10-10 2025-04-17 경북대학교 산학협력단 항노화용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827285B1 (fr) * 2001-07-10 2003-12-05 Rhodia Chimie Sa Reactif et procede pour la perfluoroalcoylation
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7098241B2 (en) 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
WO2005080322A1 (ja) 2004-02-20 2005-09-01 Astellas Pharma Inc. フルオレン誘導体
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
RU2007147844A (ru) * 2005-05-23 2009-06-27 Джапан Тобакко Инк. (Jp) Пиразольное соединение и содержащее его терапевтическое средство для лечения сахарного диабета
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
FR2936173B1 (fr) * 2008-09-22 2012-09-21 Snecma Procede pour la fabrication d'une piece en titane avec forgeage initial dans le domaine beta
AR074797A1 (es) 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
EP2423176A4 (en) * 2009-04-22 2012-11-07 Astellas Pharma Inc CARBOXYLIC ACID COMPOUND
WO2014142291A1 (ja) * 2013-03-15 2014-09-18 日本たばこ産業株式会社 フルオレン化合物の水和物、およびその結晶
PL2975028T3 (pl) * 2013-03-15 2018-10-31 Japan Tobacco, Inc. Związek pirazoloamidowy i jego zastosowania medyczne
TW201536748A (zh) 2013-07-01 2015-10-01 Japan Tobacco Inc 茀－醯胺化合物及其醫藥用途
TW201536749A (zh) 2013-07-01 2015-10-01 Japan Tobacco Inc 吡唑－醇化合物及其醫藥用途

Also Published As

Publication number Publication date
NO2975028T3 (es) 2018-07-21
ES2663789T3 (es) 2018-04-17
ME03090B (me) 2019-01-20
JP2018188449A (ja) 2018-11-29
WO2014142290A1 (ja) 2014-09-18
SI2975028T1 (en) 2018-07-31
CN105051015B (zh) 2018-09-25
EP2975028A4 (en) 2016-08-17
PH12015501993B1 (en) 2016-01-11
MX2015012743A (es) 2016-02-19
JP2018021061A (ja) 2018-02-08
RS57188B1 (sr) 2018-07-31
EP3805205A1 (en) 2021-04-14
US20140296315A1 (en) 2014-10-02
DK2975028T3 (en) 2018-03-12
MY182884A (en) 2021-02-05
US20160074364A1 (en) 2016-03-17
EP2975028B1 (en) 2018-02-21
IL241355B (en) 2019-03-31
BR112015022077A2 (pt) 2017-07-18
CA2904985A1 (en) 2014-09-18
KR102226096B1 (ko) 2021-03-09
SMT201800196T1 (it) 2018-05-02
PL2975028T3 (pl) 2018-10-31
US20180256547A1 (en) 2018-09-13
SG11201507327TA (en) 2015-10-29
PT2975028T (pt) 2018-03-29
TW201501711A (zh) 2015-01-16
RU2664532C2 (ru) 2018-08-20
CL2015002608A1 (es) 2016-03-04
JP2022000453A (ja) 2022-01-04
PE20151595A1 (es) 2015-11-24
RU2015144182A3 (es) 2018-03-06
US9040717B2 (en) 2015-05-26
AU2014230569B2 (en) 2017-11-23
CY1120173T1 (el) 2018-12-12
LT2975028T (lt) 2018-04-10
EP2975028A1 (en) 2016-01-20
HK1215808A1 (en) 2016-09-15
CA2904985C (en) 2021-07-20
JP2020189855A (ja) 2020-11-26
IL241355A0 (en) 2015-11-30
PH12015501993A1 (en) 2016-01-11
TWI633885B (zh) 2018-09-01
JP2015024984A (ja) 2015-02-05
HRP20180635T1 (hr) 2018-06-01
US20200163937A1 (en) 2020-05-28
CN105051015A (zh) 2015-11-11
AU2014230569A1 (en) 2015-10-08
KR20150131221A (ko) 2015-11-24
JP6208603B2 (ja) 2017-10-04
JP2019194197A (ja) 2019-11-07
HUE036672T2 (hu) 2018-07-30
RU2015144182A (ru) 2017-04-24
EP3348545A1 (en) 2018-07-18

Similar Documents

Publication Publication Date Title
MX373716B (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
NI201400108A (es) Compuestos de heterociclilo
EP2896022A4 (en) DRUGS CHARGE REGULATOR
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
JO3310B1 (ar) مشتقات إندوليزين جديدة وطريقة لإنتاجها وتركيبات صيدلانية تحتوي عليها
PH12015502178A1 (en) Pyridinylpyrazoloquinoline compound
BR112016029825A2 (pt) composto
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
EA201591024A1 (ru) Димерные соединения
EA201300990A1 (ru) Парентеральное введение тапентадола
EA201690894A1 (ru) Феноксиэтилы
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы
MX373389B (es) Derivado de sulfonamida y uso farmaceutico del mismo.
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
PH12017501071B1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MX2016015856A (es) Derivados de naftiridinadiona.

Legal Events

Date Code Title Description
FG Grant or registration